News from the FDA/CDC

FDA: PrEP indication updated to include adolescents at risk of HIV infection


 

  • inconsistent or no condom use.
  • diagnosis of sexually transmitted infections.
  • exchange of sex for commodities (such as money, food, shelter, or drugs).
  • use of illicit drugs or alcohol dependence.
  • incarceration.
  • partner(s) of unknown HIV-1 status with any of the factors listed above.

Dosage and administration

2.1 Testing prior to initiation of Truvada for treatment of HIV-1 infection or for HIV-1 PrEP

Prior to or when initiating Truvada, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1)].

Prior to initiation and during use of Truvada, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus

Pages

Recommended Reading

FDA approves raltegravir for newborns at risk for HIV-1 infection
MDedge Pediatrics
Teens with PID underscreened for HIV, syphilis
MDedge Pediatrics
HHS creates new religious freedoms division
MDedge Pediatrics
Trial seeks improved regimens for pregnant women with HIV
MDedge Pediatrics
nPEP for HIV: Updated CDC guidelines available for primary care physicians
MDedge Pediatrics
FDA approves complete combo tablet for HIV
MDedge Pediatrics
Time to HIV rebound in infants off ART linked to birth health
MDedge Pediatrics
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Pediatrics
Emotional regulation training lowers risk of adolescents having sex
MDedge Pediatrics
FDA seeks comments on pediatric HIV product development
MDedge Pediatrics